Eribulin in advanced breast cancer: safety, efficacy and new perspectives

被引：9

作者：

Garrone, Ornella ^{[1
]}

Miraglio, Emanuela ^{[1
]}

Vandone, Anna Maria ^{[1
]}

Vanella, Paola ^{[1
]}

Lingua, Daniele ^{[1
]}

Merlano, Marco C. ^{[1
]}

机构：

[1] Med Oncol AOS Croce & Carle Osped Insegnamento, Cuneo, Italy

来源：

FUTURE ONCOLOGY | 2017年 / 13卷 / 30期

关键词：

chemotherapy; eribulin; mechanism of action; metastatic breast cancer; new treatment; HALICHONDRIN-B ANALOG; ADVANCED SOLID TUMORS; PHASE-I; LOCALLY RECURRENT; 1ST-LINE THERAPY; CONSORTIUM TRIAL; DOSE-ESCALATION; POOLED ANALYSIS; MESYLATE E7389; CHEMOTHERAPY;

D O I：

10.2217/fon-2017-0283

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Eribulin is a synthetic analog of halichondrin B belonging to microtubule-targeted agents with a distinct mechanism of inhibition of microtubule dynamics. This molecule has multiple nonmitotic effects on tumor biology, exhibiting effects on epithelial-mesenchimal transition and tumor vasculature. We review here preclinical and clinical studies on eribulin. The mitotic and nonmitotic effects together with its favorable safety profile make eribulin a unique drug with high potential in the treatment of metastatic breast cancer. The new emphasis of eribulin mechanism of action on vascular remodeling, microenvironment modifications and reversal of epithelial-mesenchimal transition paves the way to rethinking the use of the drug in an immunological perspective.

引用

页码：2759 / 2769

页数：11

共 50 条

[1] Efficacy and safety of eribulin in Japanese patients (pts) with advanced breast cancer
Iwata, H.
Aogi, K.
Masuda, N.
Mukai, H.
Yoshida, M.
Rai, Y.
Taguchi, K.
Sasaki, Y.
Takashima, S.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[2] Treatment Strategy and Safety of Eribulin in Advanced Breast Cancer
Wang, Xinli
Liu, Shusong
Xue, Yan
JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2022, 32 (01): : 122 - 124
[3] Safety and efficacy of eribulin mesylate (EM) in patients with advanced breast cancer: The Royal Marsden experience
Thanopoulou, Eirini
Omarini, Claudia
Yeo, Belinda
Allen, Mark
Parton, Marina
Turner, Nicholas C.
O'Brien, Mary E. R.
Johnston, Stephen R. D.
Smith, Ian E.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[4] Safety and efficacy of eribulin in combination with gemcitabine in patients with advanced triple negative breast cancer.
Michalaki, Vasiliki
Fragulidis, Georgios
Kondis, Ioannis
Karvouni, Eleni
Dafnios, Nikolaos
Kotsiou, Antonia
Vassiliou, Ioannis
Papadimitriou, Christos
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[5] Efficacy, safety and cost of eribulin in patients with metastatic breast cancer
Paillard, Marie-Justine
Curtit, Elsa
Dobi, Erion
Mansi, Laura
Bazan, Fernando
Villanueva, Cristian
Chaigneau, Loic
Montcuquet, Philippe
Meneveau, Nathalie
Thiery-Vuillemin, Antoine
Nerich, Virginie
Pivot, Xavier
BULLETIN DU CANCER, 2015, 102 (09) : 737 - 748
[6] EMBRACE, eribulin, and new realities of advanced breast cancer
Lin, Nancy U.
Burstein, Harold J.
LANCET, 2011, 377 (9769): : 878 - 880
[7] Safety and efficacy of eribulin in patients with locally advanced or metastatic breast cancer: A phase IV study in India
Choudhary, Vaibhav
Satheesh, C. T.
Bose, Chinmoy K.
Rajan, Shiv
Prakash, Ss
Desai, Chirag
Lin, Xiao
Patil, Balaji
Chaudhari, Sameer
Gupta, Sudeep
ANNALS OF ONCOLOGY, 2022, 33 : S537 - S537
[8] Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy
Doherty, Mark K.
Morris, Patrick G.
INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2015, 7 : 47 - 58
[9] Efficacy and safety profile of eribulin mesylate in advanced breast cancer: Single-centre experience from India
Sharma, A.
Doval, D. C.
Dutta, K.
Goyal, P.
Bajaj, R.
Sharma, M.
Jain, P.
ANNALS OF ONCOLOGY, 2016, 27
[10] Safety and efficacy of eribulin in patients with advanced breast cancer treated outside of a clinical trial: A single institution experience
Kessler, Luisa
Bergh, Jonas
Foukakis, Theodoros
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 4 5 →